What the FDA labels say about taking them together
Bosutinib and voriconazole
Voriconazole's FDA label of February 26, 2026 names bosutinib in its drug interactions section; the bosutinib label PlainMeds reads does not name voriconazole. The voriconazole label: “Avoid concomitant use of VFEND. If concomitant use cannot be avoided, dose reduction of the tyrosine kinase inhibitor is recommended. Refer to the prescribing information for the relevant product.”
Check it at the source: the bosutinib FDA label on DailyMed (effective March 10, 2026, Pfizer Laboratories Div Pfizer Inc); the voriconazole FDA label on DailyMed (effective February 26, 2026, Roerig).
What does the bosutinib label say about voriconazole?
Bosutinib's label (effective March 10, 2026) does not name voriconazole in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (BOSULIF), NDA203341 (Pf Prism Cv), as published by Pfizer Laboratories Div Pfizer Inc, effective March 10, 2026 (SPL set adc84ad5-a04d-4fee-9ba8-91f7abd928e3), via openFDA; the full label on DailyMed
What does the voriconazole label say about bosutinib?
Voriconazole label, drug interactionsDrug/Drug Class (Mechanism of Interaction by Voriconazole): Tyrosine kinase inhibitors (including but not limited to axitinib, bosutinib, cabozantinib, ceritinib, cobimetinib, dabrafenib, dasatinib, nilotinib, sunitinib, ibrutinib, ribociclib) (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Drug Plasma Exposure Likely to be Increased; Prevention or Management Recommendations: Avoid concomitant use of VFEND. If concomitant use cannot be avoided, dose reduction of the tyrosine kinase inhibitor is recommended. Refer to the prescribing information for the relevant product.
Source: FDA drug label (VFEND), NDA021630 (Pf Prism Cv), as published by Roerig, effective February 26, 2026 (SPL set ce3ef5cf-3087-4d92-9d94-9eb8287228db), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Bosutinib | Voriconazole | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma | Fungal infections |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | n/a | $1.88 per tablet 200 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once